[go: up one dir, main page]

CR20110478A - Tratamiento del cancer de pancreas - Google Patents

Tratamiento del cancer de pancreas

Info

Publication number
CR20110478A
CR20110478A CR20110478A CR20110478A CR20110478A CR 20110478 A CR20110478 A CR 20110478A CR 20110478 A CR20110478 A CR 20110478A CR 20110478 A CR20110478 A CR 20110478A CR 20110478 A CR20110478 A CR 20110478A
Authority
CR
Costa Rica
Prior art keywords
cancer treatment
pancreas cancer
iodofenilamino
metoxifenil
dihydroxypropyl
Prior art date
Application number
CR20110478A
Other languages
English (en)
Inventor
Mark S Chapman
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110478(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of CR20110478A publication Critical patent/CR20110478A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con el campo de la oncología y con el uso de la (S)-N-(3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO)-6-METOXIFENIL)-1-(2,3-dihidroxipropil) ciclopropano-1-sulfonamida o de una sal farmaceuticamente aceptable de esta.
CR20110478A 2009-03-11 2011-09-09 Tratamiento del cancer de pancreas CR20110478A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15939709P 2009-03-11 2009-03-11

Publications (1)

Publication Number Publication Date
CR20110478A true CR20110478A (es) 2011-10-24

Family

ID=42129806

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110478A CR20110478A (es) 2009-03-11 2011-09-09 Tratamiento del cancer de pancreas

Country Status (20)

Country Link
US (1) US20120053211A1 (es)
EP (1) EP2405907A1 (es)
JP (1) JP2012520319A (es)
KR (1) KR20110128916A (es)
CN (1) CN102438609A (es)
AU (1) AU2010224108A1 (es)
BR (1) BRPI1009435A2 (es)
CA (1) CA2754891A1 (es)
CL (1) CL2011002234A1 (es)
CR (1) CR20110478A (es)
EA (1) EA201101305A1 (es)
IL (1) IL215037A0 (es)
MA (1) MA33109B1 (es)
MX (1) MX2011009494A (es)
SG (1) SG174271A1 (es)
SV (1) SV2011004017A (es)
TN (1) TN2011000456A1 (es)
TW (1) TW201100081A (es)
UY (1) UY32486A (es)
WO (1) WO2010105082A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2487628T3 (es) 2009-11-04 2014-08-22 Novartis Ag Derivados de sulfonamida heterocíclica útiles como inhibidores de MEK
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
KR102459801B1 (ko) * 2016-07-15 2022-10-26 에이치투 워터 테크놀로지스 엘티디 수소가 풍부한 물 및 기타 제품을 제조하기 위한 조성물
KR101980809B1 (ko) * 2017-09-29 2019-05-21 대한민국 귀리껍질 추출물을 포함하는 췌장암의 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9022A (en) * 1852-06-15 Organ
US8005A (en) * 1851-04-01 He ne y bo o t
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007121481A2 (en) * 2006-04-18 2007-10-25 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
AP2817A (en) * 2007-07-30 2013-12-31 Ardea Biosciences Inc Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof

Also Published As

Publication number Publication date
EP2405907A1 (en) 2012-01-18
BRPI1009435A2 (pt) 2016-03-01
SG174271A1 (en) 2011-10-28
WO2010105082A1 (en) 2010-09-16
CN102438609A (zh) 2012-05-02
TW201100081A (en) 2011-01-01
US20120053211A1 (en) 2012-03-01
JP2012520319A (ja) 2012-09-06
AU2010224108A1 (en) 2011-09-22
CA2754891A1 (en) 2010-09-16
UY32486A (es) 2010-10-29
TN2011000456A1 (en) 2013-03-27
KR20110128916A (ko) 2011-11-30
MA33109B1 (fr) 2012-03-01
SV2011004017A (es) 2012-01-06
EA201101305A1 (ru) 2012-04-30
IL215037A0 (en) 2011-11-30
MX2011009494A (es) 2011-10-11
CL2011002234A1 (es) 2012-01-27

Similar Documents

Publication Publication Date Title
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GT201100181A (es) "inhibidores de proteina cinasa"
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
UA116455C2 (uk) Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2015000942A1 (es) Compuestos de benceno sustituido.
SMT201400148B (it) Inibitori di jak2 e loro uso per il trattamento del cancro e di malattie mieloproliferative
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY32730A (es) Inhibidores de cyp17
PA8850801A1 (es) Compuestos útiles para inhibir chk1
HUE063145T2 (hu) Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra
EA201171367A1 (ru) Винилиндазолильные соединения
CR20110478A (es) Tratamiento del cancer de pancreas
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
HUS2100043I1 (hu) Kelátképzõk és peptid antimikrobiális vegyületek alkalmazása
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)